Journal article
Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia
Journal of clinical oncology, Vol.5(5), pp.722-730
05/01/1987
DOI: 10.1200/JCO.1987.5.5.722
PMID: 3572463
Abstract
A pilot study was conducted to determine the possible efficacy and the toxicities associated with the administration of four courses of intensive consolidation chemotherapy to patients with acute nonlymphocytic leukemia in remission. All therapy was completed within 6 months. The median duration of remission was 22 months, with 45+% of patients in remission at 3 years and few relapses to date thereafter. Sixty percent of patients experienced significant side effects after each course of therapy. The therapy appeared to be particularly efficacious for patients less than 45 years of age, since 65% are alive at 3 years and there is no projection for a median duration of remission as yet. The cytogenetic characteristics of the leukemic cells, the percentage of S phase cells, and the height of the WBC count were the most important prognostic characteristics at diagnosis.
Details
- Title: Subtitle
- Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia
- Creators
- H D PreislerA RazaA EarlyJ KirshnerM BrecherA FreemanY RustumN AzarniaR PrioreA Sandberg
- Resource Type
- Journal article
- Publication Details
- Journal of clinical oncology, Vol.5(5), pp.722-730
- DOI
- 10.1200/JCO.1987.5.5.722
- PMID
- 3572463
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/01/1987
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359696302771
Metrics
4 Record Views